US Stock MarketDetailed Quotes

IMUX Immunic

Watchlist

1.100
+0.010+0.92%

Close Mar 11 16:00 ET

1.100
0.0000.00%

Post 16:09 ET

99.09MMarket Cap-0.89P/E (TTM)

Immunic Stock Forum

Jaguar8

Feb 26 06:28

NEWS

$Immunic (IMUX.US)$
Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis
Wednesday, 26th February at 6:30 am
– Vidofludimus Calcium's Activation of Nurr1 Reduces Neuronal Loss and Injury Directly and Indirectly By Decreasing Microglial Activations in Preclinical Models –
– Top-Line Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in April –
NEW YORK, Feb. 26, 2025 /PRNewswi...

Teddy123

Feb 26 05:38

Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis

$Immunic (IMUX.US)$
Can Immunic's MS Drug Protect Neurons? New Data Reveals Promising Mechanism Ahead of Critical Trial Results

Teddy123

Feb 20 06:49

Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing

$Immunic (IMUX.US)$
Oral GLP-1 Breakthrough? New Drug Shows 250% Increase in Weight Loss Hormone

Trytosaveabit

Feb 20 06:35

update

$Immunic (IMUX.US)$ Reuters· 3 mins ago
Immunic's Oral Imu-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing

Jaguar8

Feb 20 06:31

NEWS

$Immunic (IMUX.US)$
Immunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing
NEWS PROVIDED BY
Feb 20, 2025, 07:30 ET
Immunic, Inc. Logo (PRNewsfoto/Immunic, Inc.)
– New Data Suggests that IMU-856 Could Be a Potential Oral Treatment Option for Weight Management; Program Is Phase 2 Ready –
– Dose-Dependent Increase of Endogenous GLP-1 Levels Observed in Post Hoc Analysis of Patients From Phase 1b Clinica...

Jaguar8

Jan 7 07:29

NEWS

$Immunic (IMUX.US)$
Immunic Highlights 2024 Accomplishments and Upcoming Milestones
Tuesday, 7th January at 6:30 am
– Top-Line Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in April –
– Reported Positive Outcome from Interim Analysis of Ongoing, Twin Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Both Trials on Track to Be Completed in 2026 –
– Strengthened Management Team and Board of Directors with Key Hir...

SJ66Pegasus

Dec 20, 2024 07:46

$Immunic (IMUX.US)$ https://www.sec.gov/edgar/search/#/ciks=0001280776&entityName=IMMUNIC%252C%2520INC.%2520(IMUX)%2520(CIK%25200001280776)
Anything Important?

SJ66Pegasus

Dec 20, 2024 05:31

$Immunic (IMUX.US)$ 20.6% of IMUX 's stock were hold by retail investors (Institutional hold 62.16%, and Indiser hold 17.24% . Insider buying ,not much,yet still buying.Anyway Indiser can disguised in any form, we just think like them,and play predator instead.

SJ66Pegasus

Dec 20, 2024 04:40

$Immunic (IMUX.US)$ Scam Huge Scam

71261076

Dec 17, 2024 16:49

$Immunic (IMUX.US)$ The issue is they really have no product with final data while competitors move in with therapies that are FDA approved. The market for MS has many approved therapies. With each therapy approved, there is no immediate need for another one. Typically, this extends the approval time period. Even if data is very positive May of 2025 it will take 6 to 12 months for FDA to approve. So you will not see any real significant moves on this until 2026. By that time, they will need more...

No comment yet

IMUX Immunic

Immunic Stock Forum

Trending Stocks